



Zeal & Innovation in **M**edicine

Ref No.: ZLL/CS/BSE/NSE

Date: 11.02.2026

BSE Limited, Corporate Relationship Department P. J. Towers, Dalal Street, Mumbai- 400 001 Company Code- 541400	National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
---	---

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), we wish to inform you that the Board of Directors in their meeting held on 11th February, 2026 have considered and approved the Incorporation of Wholly owned subsidiary of the Company in Chile, LATAM region with an investment of upto USD 15,000.

The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1 /P/CI R/2023/123 dated July 13, 2023, is also enclosed as **Annexure- I**.

Kindly take the intimation on record.

Thanking you,

Yours faithfully,

For **ZIM LABORATORIES LIMITED**

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Encl.: Annexure I

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172



Zeal & Innovation in **M**edicine

Annexure I

Disclosure under sub-para (1) [i.e., Acquisition(s) (including agreement to acquire)] of Para (A) of Part (A) of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Entity Name: ZIM Laboratories SpA or any other name as approved by the regulatory authority. Turnover: NIL (As the Company is yet to be incorporated)
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	At present, the said transaction is not a related party transaction. However, once is entity is incorporated and investment in the capital of the said entity is completed, the said entity will be termed as related party to the Company and any transaction with the entity would be categorised as related party transaction. Dr. Anwar Daud and Mr. Zulfiquar Kamal, Promoters of the Company would be appointed as Directors on the Board of ZIM Laboratories SpA.
3	Industry to which the entity being acquired belongs	Pharmaceutical
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The incorporation of Wholly owned subsidiary is with an objective of expansion and development of business in the LATAM region.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Any approvals or permission, if required for incorporation of the entity in Chile, LATAM region, would be obtained by the entity.

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172



Zeal & Innovation in **Medicine**

6	Indicative time period for completion of the acquisition	Not Applicable
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration
8	Cost of acquisition and/or the price at which the shares are acquired	ZIM Laboratories Limited would invest upto USD 15,000 or any equivalent amount in the relevant currency in the share capital of the Wholly Owned subsidiary.
9	Percentage of shareholding /control acquired and / or number of shares acquired	After the proposed investment, the incorporated entity would be the Wholly owned subsidiary of the Company.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable as the Company is yet to be Incorporated.

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960